Edwards Lifesciences slips as Oppenheimer downgrades on upcoming data

[Business on Wall Street in Manhattan]
Pgiam/iStock via Getty Images

Shares of Edwards Lifesciences (NYSE:EW [https://seekingalpha.com/symbol/EW]) fell on Wednesday after Oppenheimer downgraded the cardiac device maker to Perform from Outperform, citing concerns over two upcoming trial readouts for the company’s Sapien line of heart valves.

The rating change comes as the Irvine, California-based MedTech is set to take part in the annual Transcatheter Cardiovascular Therapeutics (TCT) conference later this month to present data from its PARTNER-3 and ENCIRCLE trials.

Analyst Suraj Kalia argued that data from the trials, designed to evaluate Edwards’ (NYSE:EW [https://seekingalpha.com/symbol/EW]) SAPIEN 3 and SAPIEN M3 heart valve systems, respectively, are unlikely to be “straightforward, and ensuing post-hoc debate could paint a confusing picture.”

“Our caution stems from our fundamental analysis on key product designs, statistical analysis of trial outcomes, and proprietary survey,” the analyst wrote, removing his price target on the stock.

Oppenheimer’s downgrade on Edwards (NYSE:EW [https://seekingalpha.com/symbol/EW]) comes a day after Evercore ISI upgraded the company to outperform from equal weight, citing a near-term turnaround in its topline performance. [https://seekingalpha.com/news/4502402-edwards-lifesciences-upgraded-evercore-upcoming-topline-inflection]

MORE ON EDWARDS LIFESCIENCES

* Edwards Lifesciences: A Market Leader Stuck In 'Hold' Mode Despite Solid Growth [https://seekingalpha.com/article/4815476-edwards-lifesciences-stock-market-leader-stuck-hold-mode-despite-solid-growth]
* Edwards Lifesciences: Gradually Winning My Investment Heart [https://seekingalpha.com/article/4814619-edwards-lifesciences-gradually-winning-my-investment-heart]
* Edwards Lifesciences Corporation (EW) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4804339-edwards-lifesciences-corporation-ew-q2-2025-earnings-call-transcript]
* Edwards Lifesciences upgraded at Evercore on upcoming 'topline inflection' [https://seekingalpha.com/news/4502402-edwards-lifesciences-upgraded-evercore-upcoming-topline-inflection]
* Edwards Lifesciences launches $500M accelerated share buyback [https://seekingalpha.com/news/4487229-edwards-lifesciences-launches-500m-accelerated-share-buyback]